Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 948 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
Year : 2018  |  Volume : 22  |  Issue : 1  |  Page : 132-157

Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force

1 Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India
2 Department of Internal Medicine, Diabetes & Endocrinology, St. Francis Hospital, Nsambya, Kampala, Uganda
3 Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India
4 Department of Endocrinology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India
5 Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
6 Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt
7 Department of Internal Medicine, Hindu Mandal Hospital, Dar es Salaam, Tanzania
8 Department of Endocrinology, Al Jahra Hospital, Al Jahra, Kuwait
9 Department of Endocrinology, Norvic International Hospital and Medical College, and Hospital for Advanced Medicine and Surgery, Maharajganj, Kathmandu, Nepal
10 Department of Diabetes, Faculty of Internal Medicine, Royal Oman Police Hospital, Muscat, Oman
11 Department of Pharmacology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka
12 Department of Medicine, Tribhuvan University Teaching Hospital, Maharajganj, Kathmandu, Nepal
13 Department of Medicine, Teaching Hospital, Jaffna, Sri Lanka
14 Department of Medicine, Tawam Hospital, Al Ain, UAE
15 Department of Internal Medicine, Diabetes & Metabolism Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt
16 Department of Internal Medicine, Faculty of Medicine, YARSI University, Jakarta, Indonesia
17 Department of Internal Medicine, Kathmandu University Hospital, Dhulikhel, Nepal
18 Department of Endocrinology, ADK Hospitals, Male, Maldives
19 Department of Endocrinology, Kenyatta National Hospital, Nairobi, Kenya
20 Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaounde, Cameroon
21 Department of Endocrinology, University of Medicine 2, Yangon, Myanmar
22 Department of Medicine, University of Medicine 2, Yangon, Myanmar
23 Center of Diabetes, Clinic of Internal Diseases, Asfendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan
24 Department of Endocrinology, Shaukat Khanum Hospital and Research Center, Lahore, Pakistan
25 Department of Endocrinology, Metabolism and Diabetes, All India Institute of Medical Sciences, Pune, Maharashtra, India
26 Department of Endocrinology and Diabetes, Chellaram Diabetes Institute, Pune, Maharashtra, India
27 Department of Medicine, University of Delhi, New Delhi, India
28 Department of Endocrinology, Diabetes and Metabolism, Wilshire Cardiovascular and Endocrine Center of Excellence, Lahore, Pakistan
29 Department of Medicine, MLN Medical College, Allahabad, Uttar Pradesh, India
30 Department of General Medicine, Pondicherry Institute of Medical Sciences, Puducherry, India

Correspondence Address:
Sanjay Kalra
Department of Endocrinology, Bharti Hospital, Karnal, Haryana
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijem.IJEM_556_17

Rights and Permissions

For decades, sulfonylureas (SUs) have been important drugs in the antidiabetic therapeutic armamentarium. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. It has to be borne in mind that the adverse events associated with SUs should not be ascribed to the whole class, as many modern SUs, such as glimepiride and gliclazide modified release, are associated with better safety profiles. Furthermore, individualization of treatment, using SUs in combination with other drugs, backed with careful monitoring and patient education, ensures maximum benefits with minimal side effects. The current guidelines, developed by experts from Africa, Asia, and the Middle East, promote the safe and smart use of SUs in combination with other glucose-lowering drugs.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded1769    
    Comments [Add]    
    Cited by others 27    

Recommend this journal